Diabetes Prevalence in Iran Surpasses Global Estimates: Experts Call for Greater Investment in Innovative Therapies

The 6th International and 8th National Congress on Advances in Endocrinology and Metabolism convened in Isfahan this week, bringing together leading experts in the field. During the event, Prof. Bagher Larijani, Director of the Endocrinology and Metabolism Research Institute (EMRI) at Tehran University of Medical Sciences, delivered a keynote address highlighting the growing burden of diabetes, particularly in the Middle East and North Africa (MENA) region.

“Today, nearly eight million Iranians live with diabetes—a figure that exceeds global projections and poses a significant challenge to the nation’s healthcare system,” Prof. Larijani stated.

Emphasizing the promise of emerging therapies, Prof. Larijani discussed advances in regenerative medicine, particularly cellular and gene-based therapies for diabetes management. These approaches aim to restore the function of insulin-producing beta cells, potentially revolutionizing diabetes treatment and improving long-term outcomes.

He highlighted the success of islet transplantation, noting that the use of glucocorticoid-free immunosuppressive regimens has led to sustained insulin independence and improved metabolic control in patients with type 1 diabetes.

Recent developments in stem cell–derived islet transplantation were also discussed, with Prof. Larijani emphasizing that these techniques provide a renewable source of beta cells, significantly reducing dependence on limited donor availability.

Despite global progress, Prof. Larijani pointed out that the number of clinical trials and research studies on cell-based diabetes therapies in Asia, including Iran, remains limited. He called for greater investment in research and innovation to ensure the region does not fall behind in adopting cutting-edge therapeutic technologies.

In his closing remarks, Prof. Larijani underscored the importance of international collaboration and urged health policymakers to prioritize diabetes research and innovation. “With continued effort and strategic investment, we can advance the quality of care and improve the lives of millions living with diabetes in Iran and across the region,” he concluded.